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http://dx.doi.org/10.1016/j.pedneo.2Background: The bacillus CalmetteeGue´rin (BCG) reaction is not included in the classical clin-
ical criteria for Kawasaki disease (KD). However, a reaction at the BCG inoculation site has
been mentioned among the “other clinical findings” that are present in about 30e50% of KD
patients. The objective of this study was to investigate the clinical characteristics of KD
patients with reactions at the BCG inoculation site.
Methods: A retrospective study of all patients diagnosed with KD between September 2000 and
August 2010 was performed. The clinical presentations, laboratory results, treatment
outcomes, and coronary artery abnormalities in the BCG-reactive [BCG(þ)] and BCG-
nonreactive [BCG(e)] groups were analyzed and compared.
Results: In total, 145 patients with KD diagnosed at our institution were included; 46 (31.7%) had
a reactionat theBCG inoculation site.TheBCG(þ) groupwas younger than theBCG(e) group.Labo-
ratory results showed higherwhite blood cell counts, platelet counts, and serum potassium levels,
and lower low-density lipoprotein levels in theBCG(þ) group.TheBCG(þ) grouphada shorter fever
duration before intravenous immunoglobulin treatment and a shorter total fever duration than the
BCG(e) group. Multivariable logistic regression analysis showed that the age at diagnosis was the
only factor significantly associated with a reaction at the BCG inoculation site in KD patients.
Conclusions: In countries with a national BCG vaccination program, a reaction at the BCG inocula-
tion site could be a useful and early diagnostic sign of KD among younger patients, especially those
younger than 6 months.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, 325 Cheng-Kung Road,
ROC.
om.tw (M.-C. Tsai).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
012.10.003
44 C.-C. Lai et al1. Introduction
clinical criteria published by the American Heart Associa-Kawasaki disease (KD), an acute febrile, self-limiting
vasculitis of unknown etiology that occurs predominantly
in children younger than 5 years, was first described by
Tomisaku Kawasaki in 1967 in Japan.1 The clinical criteria
include fever for 5 days or more, and the following five
principal clinical symptoms: polymorphous exanthema,
nonpurulent bilateral conjunctivitis, changes in the lips or
oral cavity, changes in the peripheral extremities, and
a cervical lymph node >1.5 cm in diameter. The diagnosis is
made when the child has experienced fever for 5 days or
more, has four of the other five signs, and shows no
evidence of another disease with similar clinical features.2
In addition to the diagnostic criteria, a broad range of
nonspecific clinical features can be observed, including
irritability, aseptic meningitis, cough, vomiting, diarrhea,
abdominal pain, gall bladder hydrops, arthralgia, arthritis,
hypoalbuminemia, liver function impairment, sterile
pyuria, and a reaction at the bacillus CalmetteeGue´rin
(BCG) inoculation site.2,3
Patients with KD who displayed erythema at the BCG
inoculation site were first described by Kawasaki in 1970.4 A
reaction at the BCG site is not included in the classical
clinical diagnostic criteria for KD, published by the Amer-
ican Heart Association. However, a reaction at the BCG
inoculation site is mentioned among the “other clinical
findings” that are present in about 30e50% of KD
patients.2,3,5,6 The prevalence of a reaction at the BCG
inoculation site is even higher than the incidence of
cervical lymphadenopathy among patients with complete
KD aged 3e20 months.6 The reason for this reaction in
children with KD is still unclear. However, previous studies
have suggested that cross-reactivity occurs between
specific epitopes on the mycobacterial 65-kDa heat-shock
protein and the human homologue, heat-shock protein
65.7,8
The associations between the reaction at the BCG
inoculation site and the principal clinical signs, laboratory
results, treatment outcome, and coronary artery involve-
ment in KD patients are unclear. The purpose of this study
was to investigate the clinical characteristics of KD patients
with a reaction at the BCG inoculation site.2. Methods
The medical records of 145 KD patients who were treated in
our institution from September 2000 to August 2010 were
reviewed. The reaction at the BCG inoculation site, defined
as any redness, induration, or crust formation, was recor-
ded precisely before and during hospitalization in all of
these patients. All the patients with KD had received a BCG
vaccination before 1 month of age. We divided these
patients into two groups according to the reaction at the
BCG inoculation site. The clinical manifestations of KD,
laboratory results, coronary artery abnormalities, and
treatment outcomes of the two groups were analyzed and
compared. The study was approved by the hospital insti-
tutional review board, and the requirement for individual
consent was waived for this retrospective study.The diagnosis of KD was made in accordance with the
tion. Incomplete KD is defined as an unexplained fever for
5 days or more associated with two or three of the principal
clinical features of KD but with cardiac or coronary artery
involvement.2 The duration of the febrile period was
counted from the onset of fever until intravenous immu-
noglobulin (IVIG) treatment had started (pre-IVIG fever) or
the fever had subsided completely (total fever). The
Japanese Ministry of Health criteria classify coronary
arteries as abnormal if the internal lumen diameter is
>3 mm in children younger than 5 years or >4 mm in
children 5 years or older; if the internal diameter of the
segment is 1.5 times greater than that of the adjacent
segment; or if the coronary lumen is clearly irregular.5
High-dose IVIG (2 g/kg delivered in a single dose or 1 g/kg
given for 2 days) and aspirin (60 mg/kg per day) were given
during the acute stage when the diagnosis had been
confirmed. After the fever had subsided for 48 hours, we
reduced the aspirin dose to 3e5 mg/kg per day to inhibit
platelet aggregation. Failure of the body temperature to
normalize within 48 hours of treatment with the first dose of
IVIG was defined as resistant fever, which was treated with
a second dose of IVIG at 2 g/kg. Failure of the second IVIG
treatment prompted treatment with a third dose of IVIG.
Low-dose aspirin was stopped 3 months later if the patient
showed no coronary artery involvement on echocardiog-
raphy. We prescribed an alternative platelet aggregation
inhibitor (dipyridamole, 5 mg/kg per day) in patients with
a glucose-6-phosphate dehydrogenase deficiency. If there
was echocardiographic evidence of coronary involvement,
aspirin was continued for as long as the abnormality
persisted.
All parametric data are expressed as mean  standard
deviation or percentage as appropriate. Continuous data
were compared using the Student t test. Significance of
differences in the percentages and rates of incidence
between the two groups were compared using the c2 test
with Yates’ correction. Fisher’s exact probability test was
applied when examining variables with a low incidence. All
parameters were initially examined by means of univariate
analysis; parameters with p < 0.05 as statistical signifi-
cance were introduced into the multivariate analysis, in
which all variables were continuous data. Binary logistic
regression and odds ratios were implemented to estimate
possible correlations between the factors analyzed and the
incidence of a reaction at the BCG inoculation site in KD
patients. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was
used for all statistical evaluations. A p value <0.05 was
considered statistically significant.3. Results
Of the 145 KD patients reviewed, 46 (31.7%) had a reaction
at the BCG inoculation site [BCG(þ) group], whereas 99
patients (68.3%) had no reaction at the BCG inoculation site
[BCG(e)]. All the KD patients with a reaction at the BCG
inoculation site were younger than 20 months of age
(range, 3e20 months). The age-specific percentage of KD
patients who had a reaction at the BCG inoculation site was
highest in patients younger than 6 months of age (17 of 25
BCG inoculation site reaction in KD patients 45patients, 68.0%; Figure 1). In the BCG(þ) group, the
percentage of male patients was significantly higher than
that of female patients (67.4% vs. 32.6%, respectively,
p Z 0.018).
Table 1 summarizes the clinical manifestations and
laboratory results for these patients. The BCG(þ) group was
younger than the BCG(e) group (9.0  4.9 months vs.
29.0  25.3 months, respectively, p < 0.001). Patients in
the BCG(þ) group had higher white blood cell counts,
platelet counts, and serum potassium levels, and lower
low-density lipoprotein levels. The BCG(þ) group had lower
concentrations of hemoglobin, serum C-reactive protein,
and serum cholesterol, higher serum sodium level and total
cholesterol concentration, and higher incidence of pyuria
compared with the BCG(e) group, although these differ-
ences were not significant. The major clinical manifesta-
tions did not differ significantly between the BCG(þ) and
BCG(e) groups. The BCG(þ) group had a shorter pre-IVIG
fever duration than did the BCG(e) group (5.9  1.9 vs.
7.5  3.0 days, respectively, pZ 0.001) and a shorter total
fever duration (7.2  2.0 vs. 8.5  3.0 days, respectively,
pZ 0.008). However, there was no difference between the
two groups in the fever duration of the post-IVIG treatment
or the length of hospital stay.
Six patients (13.0%) were diagnosed with incomplete KD
in the BCG(þ) group, and 14 patients (14.1%) had incom-
plete KD in the BCG(e) group; this difference was not
significant. In the BCG(þ) group, four patients had persis-
tent fever after the first dose of IVIG. Three responded to
a second dose of IVIG, and the remaining patient required
a third dose of IVIG. In the BCG(e) group, six patients had
persistent fever after the first dose of IVIG was adminis-
tered. Three responded to a second dose, whereas the
other three patients required a third dose of IVIG. There
was no significant difference between the two groups in
their requirement for IVIG retreatment. Two patients in the
BCG(þ) group and seven patients in the BCG(e) group had
coronary artery abnormalities, but this difference was not
significant.
To investigate the association between a reaction at the
BCG inoculation site and each major clinical manifestation
of KD in KD patients of different ages, we compared the0
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Figure 1 Age distribution of KD and age-specific rates of rea
BCG Z bacillus CalmetteeGue´rin; KD Z Kawasaki disease.prevalence of a reaction at the BCG inoculation site and the
major clinical manifestations of KD in the patients younger
and older than 2 years. KD patients younger than 2 years
had a lower prevalence of cervical lymphadenopathy and
a higher frequency of a reaction at the BCG inoculation site
than did KD patients aged 2 years or older (Table 2). The
prevalence of a reaction at the BCG inoculation site among
KD patients younger than 2 years was also higher than the
incidence of cervical lymphadenopathy.
Several variables, including those that differed signifi-
cantly between the BCG(þ) and BCG(e) groups (Table 1),
were tested in multivariable logistic regression analysis
(Table 3). The age at onset had an odds ratio of 0.830 (95%
confidence intervalZ 0.734e0.938, p Z 0.003), indicating
that the prevalence of a reaction at the BCG inoculation
site decreased with increasing age in KD patients. The two
groups did not differ significantly in terms of the other
variables tested.4. Discussion
In our study, a reaction at the BCG inoculation site devel-
oped more frequently in younger KD patients, especially in
those aged less than 6 months. No KD patient with a reac-
tion at the BCG inoculation was older than 20 months. This
finding is similar to that of a previous study by Takayama
et al, who reported that 36% of KD patients developed
erythema at the BCG inoculation site, with the highest rate
(88%) of reaction observed in KD patients 4e6 months after
their BCG inoculation.9 None of their KD patients showed
a reaction at the BCG inoculation site 37 months or more
after their BCG inoculations.9 It appears that the preva-
lence of this reaction in KD patients declines with time
after the BCG vaccination.
The marked leukocytosis and thrombocytosis we
observed in the KD patients with a reaction at the BCG
inoculation site suggest a more severe inflammatory
process. Similar results have been reported in several
earlier studies, in which marked leukocytosis and throm-
bocytosis were noted in younger infants, whereas higher
values for inflammatory indices were observed in older35 36-47 48-59 60
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Table 1 Comparison of the clinical manifestations and laboratory results of patients with and without a reaction at the
bacillus CalmetteeGue´rin (BCG) inoculation site.
BCG(þ)
(n Z 46)
BCG(e)
(n Z 99)
p
Age (mo) 9.0  4.9 29.0  25.3 <0.001*
Male 31 (67.4) 59 (60.0) 0.502
WBC count (109/L) 18.1  6.8 15.2  6.2 0.01*
Hb (g/L) 105.9  11.4 108.6  13.0 0.177
Platelets (109/L) 480.5  171.5 405.3  183.2 0.02*
CRP (mg/L) 90.6  62.9 110.7  80.7 0.134
AST (U/L) 83.2  125.8 86.3  114.3 0.883
ALT (U/L) 59.6  52.9 78.7  130.2 0.340
Albumin (g/L) 38.1  4.6 36.8  5.8 0.312
Serum sodium (mmol/L) 137.4  2.6 136.6  3.3 0.150
Serum potassium (mmol/L) 4.7  0.4 4.3  0.6 <0.001*
Cholesterol (mmol/L) 3.28  0.85 3.49  0.96 0.200
Triglycerides (mmol/L) 1.63  0.68 1.60  0.73 0.804
HDL-C (mmol/L) 0.63  0.31 0.60  0.27 0.574
LDL-C (mmol/L) 1.80  0.76 2.11  0.80 0.029*
Pyuria, (>10 WBCs/HPF) 18 (39.1) 27 (27.2) 0.212
Major clinical manifestations
Fever >5 d 46 (100) 99 (100) 1.000
Conjunctival injection 43 (93.5) 88 (88.9) 0.568
Skin rash 43 (93.5) 89 (89.9) 0.694
Mucosal change in the oropharynx 44 (95.7) 91 (91.9) 0.625
Change in the extremities 25 (54.3) 49 (49.5) 0.719
Cervical lymphadenopathy 13 (28.3) 40 (40.4) 0.221
Length of hospital stay (d) 5.6  2.7 6.3  3.5 0.232
Duration of pre-IVIG fever (d) 5.9  1.9 7.5  3.0 0.001*
Duration of post-IVIG fever (d) 1.3  1.1 1.1  0.6 0.159
Duration of total fever (d) 7.2  2.0 8.5  3.0 0.008*
Incomplete Kawasaki disease 6 (13.0) 14 (14.1) 0.936
Failure of the first IVIG treatment 4 (8.7) 6 (6.1) 0.824
Coronary artery abnormality 2 (4.3) 7 (7.1) 0.779
Coronary artery aneurysm 2 (4.3) 3 (3.0) 0.928
Data are expressed as means  standard deviations or n (%).
ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; BCG(þ)Z KD patients with a reaction at the BCG inoculation site;
BCG(e) Z KD patients without a reaction at the BCG inoculation site; CRP Z C-reactive protein; Hb Z hemoglobin; HDL-C Z high-
density lipoprotein cholesterol; HPF Z high-power field; IVIG Z intravenous immunoglobulin; LDL-C Z low-density lipoprotein
cholesterol; WBC Z white blood cell.
* Statistically significant.
46 C.-C. Lai et alchildren.10e12 In our study, serum potassium levels were
significantly higher in the BCG(þ) group than in the BCG(e)
group. Serum potassium is elevated in patients with
thrombocytosis because potassium is released from plate-
lets during their coagulation.13
There are several possible explanations for the shorter
time from disease onset to appropriate treatment in KD
patients with a reaction at the BCG inoculation site. First,
a reaction at the BCG inoculation site appears in the early
stages of KD. An erythematous reaction at the BCG inocu-
lation site usually appears 24e48 hours after fever onset
and forms a crust shortly after the fever subsides.9 Second,
KD patients with a reaction at the BCG inoculation site
visited a hospital earlier after the onset of the illness. In our
study, the KD patients with a reaction at the BCG inocula-
tion site usually visited a hospital 1e4 days after the onset
of the illness.6 Third, physicians always consider KD if thepatient has a reaction at the BCG inoculation site accom-
panied by fever or other major signs of KD because of the
higher prevalence of this reaction among patients with KD
than among those with other febrile illnesses.6 All of these
factors facilitate the earlier recognition of KD and the
earlier administration of the appropriate treatment in KD
patients with a reaction at the BCG inoculation site.
Many studies have demonstrated that the clinical
manifestations of KD vary with age, reflecting age-
dependent host responses to common immunological
stimuli.12,14 Of the five major clinical diagnostic criteria for
KD, all occur with equivalent frequencies at all ages, with
the exception of cervical lymphadenopathy.12,14 The prev-
alence of cervical lymphadenopathy is lower in young KD
patients than that in older KD patients. As in our study, KD
patients younger than 2 years have a lower prevalence of
cervical lymphadenopathy than do KD patients aged 2 years
Table 2 Diagnostic clinical manifestations of Kawasaki disease according to age.
<2 y (n Z 100) 2 y (n Z 45) p
Clinical manifestations
Conjunctival injection 92 (92) 39 (87) 0.366
Skin rash 90 (90) 42 (93) 0.755
Mucosal change in the oropharynx 94 (94) 41 (91) 0.501
Changes in the extremities 51 (51) 23 (51) 0.990
Cervical lymphadenopathy 25 (25) 28 (62) <0.001*
Reaction at BCG inoculation site 46 (46) 0 (0) <0.001*
Data are presented as n (%).
BCG Z bacillus CalmetteeGue´rin.
* Statistically significant.
BCG inoculation site reaction in KD patients 47or older. KD patients younger than 2 years also have
a higher frequency of a reaction at the BCG inoculation site
than do KD patients aged 2 years or older. Furthermore, the
prevalence of a reaction at the BCG inoculation site among
KD patients younger than 2 years is higher than the inci-
dence of cervical lymphadenopathy. We propose that
a reaction at the BCG inoculation site may be a useful sign
of KD in patients younger than 2 years because the preva-
lence of this reaction is high in KD patients in this age
group.
Coronary artery abnormality remains a major sequela of
KD. Previous studies found no association between a reac-
tion at the BCG inoculation site and coronary artery
abnormalities in KD patients.6,15 Our study also showed
a similar association insofar as the proportion of coronary
artery abnormalities was lower in KD patients with a reac-
tion at the BCG inoculation site than in those with no such
reaction. However, KD patients with a reaction at the BCG
inoculation site had marked leukocytosis and thrombocy-
tosis, which are associated with coronary artery abnor-
malities in KD patients.16 In these patients, the period from
symptom onset to the administration of appropriate treat-
ment was also shorter, and a shorter interval is associated
with a reduced risk of coronary artery abnormality.13,16e18
Both the timing of treatment and laboratory markers are
associated with coronary artery abnormalities in KD. TheTable 3 Multivariable logistic regression analysis of
factors associated with a reaction at the BCG inoculation
site in Kawasaki disease patients.
Variable Odds ratio (95% CI) p
Age at onset (mo) 0.830 (0.734e0.938) 0.003*
WBC count 1.000 (1.000e1.000) 0.307
Platelet count 1.000 (1.000e1.000) 0.253
Serum potassium 0.706 (0.119e4.182) 0.701
LDL 1.006 (0.982e1.030) 0.647
Duration of pre-IVIG fever 0.684 (0.286e1.636) 0.394
Duration of total fever 0.827 (0.328e2.087) 0.688
BCG Z bacillus CalmetteeGue´rin; CI Z confidence interval;
IVIG Z intravenous immunoglobulin; LDL Z low-density lipo-
protein; WBC Z white blood cell.
* Statistically significant.actual association between coronary artery abnormalities
and a reaction at the BCG inoculation site in KD patients
requires further investigation.
5. Conclusion
The diagnosis of KD is based predominantly on its clinical
manifestations and the exclusion of other diseases, because
no specific diagnostic test is currently available. However,
the clinical manifestations of KD vary with age. In countries
with a national BCG vaccination program, a reaction at the
BCG inoculation site could be a useful and early diagnostic
sign of KD among younger patients, especially in those
younger than 6 months. Physicians should also recognize
the possibility of KD in patients younger than 2 years with
three or fewer of the clinical criteria for KD but with
a reaction at the BCG inoculation site.References
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